Attached files

file filename
EX-10.3 - FORM OF COMMERCIAL SECURITY AGREEMENT - ABVC BIOPHARMA, INC.f8k012119ex10-3_americanbri.htm
EX-10.2 - PROMISSORY NOTE ENTERED BY AMERICAN BRIVISION (HOLDING) CORPORATION - ABVC BIOPHARMA, INC.f8k012119ex10-2_americanbri.htm
EX-10.1 - BUSINESS LOAN AGREEMENT ENTERED BY AND BETWEEN CATHAY BANK AND AMERICAN BRIVISIO - ABVC BIOPHARMA, INC.f8k012119ex10-1_americanbri.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 1, 2019 (January 21, 2019)

 

AMERICAN BRIVISION (HOLDING) CORPORATION 
(Exact name of registrant as specified in its charter)

 

Nevada   333-91436   26-0014658
(State or other jurisdiction
of incorporation)
  (Commission File Number)  

(IRS Employer

Identification No.)

 

44370 Old Warm Springs Blvd.

Fremont, CA 94538

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (845) 291-1291

 

Check the appropriate box below if the Form 8-K/A filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 1.01  Entry into a Material Definitive Agreement.

On January 21, 2019, American BriVision (Holding) Corporation (the “Company”) received a loan in the amount of $500,000 from Cathay Bank (the “Bank”) pursuant to a business loan agreement (the “Loan Agreement”) entered by and between the Company and Bank on January 8, 2019 and a promissory note (the “Note”) executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the “Maturity Date”) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the “Regular Interest Rate”) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the “Index”) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.

In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee executed a commercial guaranty (the “Guaranty”) to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc., which will become a wholly-owned subsidiary of the Company upon closing of the mergers (the “Mergers”) with the Company as disclosed in a current report on Form 8-K filed on February 5, 2018. Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc., which will also become a wholly-owned subsidiary of the Company upon closing of the Mergers.

 In addition, on January 8, 2019, each of the Company and American BriVision Corporation (“American BriVision”), a wholly-owned subsidiary of the Company, signed a commercial security agreement (the “Security Agreement”) to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and American BriVision (each, a “Grantor”, and collectively, the “Grantors”) granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank.

The forgoing description of the Loan Agreement, Note and Security Agreement is qualified in its entirety by reference to the respective agreements, a copy of which are attached hereto as Exhibits 10.1, 10.2 and 10.3 and hereby incorporated by reference into this Item 1.01.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 is hereby incorporated by reference.

Item 9.01. Financial Statements and Exhibits. 

 (d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K. 

Exhibit No.   Description
     
10.1   Business Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation
10.2   Promissory Note entered by American BriVision (Holding) Corporation
10.3   Form of Commercial Security Agreement

 

 1 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  AMERICAN BRIVISION (HOLDING) CORPORATION  
       
 Date: February 1, 2019 By: /s/ Howard Doong  
  Name:  Howard Doong  
  Title:  Chief Executive Officer  

 

 

 2